Ensysce Biosciences, Inc. (ENSC)

0,7390 +0,1150 (+18,43%) Al cierre: 04:00PM EDT

Ensysce Biosciences, Inc.

7946 Ivanhoe Avenue
Suite 201
La Jolla, CA 92037
United States
858 263 4196
https://www.ensysce.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 7

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. D. Lynn Kirkpatrick Ph.D.	President, CEO & Director	414,77k	N/A	1957
Mr. David C. Humphrey CPA	CFO, Secretary & Treasurer	348,15k	N/A	1969
Mr. Geoffrey Birkett	Chief Commercial Officer	322k	N/A	1963
Dr. Jeffrey Millard Ph.d.	Chief Operating Officer	N/A	N/A	1976
Dr. William K. Schmidt Ph.D.	Chairman of Clinical Advisory Board & Chief Medical Officer	N/A	N/A	1951
Dr. Linda Pestano Ph.D.	Chief Development Officer	N/A	N/A	1970

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Gobierno corporativo

El ISS Governance QualityScore de Ensysce Biosciences, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.